Finance entity
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention MillerKnoll, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.4.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention MillerKnoll, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.4. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Finance story that mention Fulcrum Therapeutics, all published on March 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 114 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Fulcrum Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Recent short interest updates for Fulcrum Therapeutics and MillerKnoll signal growing investor caution as both companies navigate critical operational and macroeconomic challenges. While Fulcrum faces clinical-stage volatility following in-line earnings, MillerKnoll contends with a Hold consensus and broader pressure on the office furniture sector.
Source: themarketsdaily.com · themarketsdaily.com
Fulcrum Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
